Relay Therapeutics
RLAY
140 hedge funds and large institutions have $3.38B invested in Relay Therapeutics in 2022 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 45 increasing their positions, 38 reducing their positions, and 15 closing their positions.
73% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 15
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
18% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 38
7% more funds holding
Funds holding: 131 → 140 (+9)
1.73% more ownership
Funds ownership: 102.73% → 104.46% (+1.7%)
9% more call options, than puts
Call options by funds: $2.46M | Put options by funds: $2.26M
1% less capital invested
Capital invested by funds: $3.41B → $3.38B (-$22.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$34M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$20.5M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$12.4M |
| 4 |
NI
Nextech Invest
Zurich,
Switzerland
|
+$11.5M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$7.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$18.4M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$12.7M |
| 3 |
FAM
Fred Alger Management
New York
|
-$5.46M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$4.54M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.7M |
RLAY Hedge Fund Activity: Q1 2022 in Review
140 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q1 2022, worth a combined $3.38B — down 0.65% from $3.41B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RLAY positions and 15 closed out — a net gain of 11 holders — while 45 added to existing stakes and 38 trimmed.
The largest buyer was BVF Inc, adding an estimated $34M. The largest seller was Federated Hermes, exiting entirely with an estimated $18.4M sold.
- 140 institutional investors held Relay Therapeutics (RLAY) as of Q1 2022, up from 131 in Q4 2021.
- Funds reported $3.38B of Relay Therapeutics stock for Q1 2022, down 0.65% quarter-over-quarter.
- 26 funds opened new Relay Therapeutics positions in Q1 2022 and 15 closed out, a net change of +11 holders.
- The largest Relay Therapeutics buyer in Q1 2022 was BVF Inc, an estimated $34M added.
- The largest Relay Therapeutics seller in Q1 2022 was Federated Hermes, an estimated $18.4M sold.
Based on aggregated 13F filings for Q1 2022.